Final 3-year clinical outcomes following transcatheter aortic valve implantation with a supra-annular self-expanding repositionable valve in a real-world setting: Results from the multicenter FORWARD study.

Nicolas M D A van MieghemStephan WindeckerGanesh ManoharanJohan BosmansSabine BleizifferThomas ModineAxel LinkeWerner ScholtzDidier TchétchéAriel FinkelsteinSaki ItoRuth EisenbergEberhard Grube

Published in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2021)

The Evolut R valve maintained a favorable safety profile through 3 years in routine clinical practice. Rates of transcatheter heart valve-related adverse events were low.

Keyphrases

transcatheter aortic valve implantation
aortic valve
aortic stenosis
aortic valve replacement
clinical practice
transcatheter aortic valve replacement
ejection fraction
mitral valve
left ventricular
coronary artery disease
heart failure
atrial fibrillation
clinical trial
cross sectional